Selexis offers comprehensive and rapid solutions for stable, high yield mammalian cell lines used in recombinant protein manufacturing of therapeutic drugs. The Company's unique SURE Cell Line DevelopmentSM services and technology, which includes Selexis’ patented Selexis Genetic Elements™, reduces traditional cell line development (e.g. DHFR) from 12 months to ~5 weeks*. Additionally, Selexis Genetic Elements™ improves the yield and stability of production cell lines and has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 20 fold.
Selexis Genetic Elements™ provides a number of key significant advantages over traditional approaches including:
- High Yield: Predictable high expression levels;
- Speed: High productivity clones approximately 5 weeks;
- Expression: High levels and long-term expression of therapeutic proteins;
- Stability: Not associated with chromosomal rearrangements nor chromosomal breaks;
- Effective: Very effective in a variety of cell lines;
- Regulatory: Selexis Genetic Elements™ cell lines can be easily analyzed for regulatory approval.
Selexis is committed to competitive, comprehensive and rapid solutions for stable and high yield "Cell Line Development" and "Protein Manufacturing". Selexis' technology platform addresses limitations in current protein manufacturing capacities.
